Jones Day

Jones Day has bolstered its financial markets practice with the addition of a former Baker McKenzie special counsel. 

A judge has rejected Aristocrat’s bid for orders requiring competitor Light & Wonder to hand over documents to be placed “in an envelope” for speedy production should its appeal of a decision ordering that it produce the documents to Aristocrat for possible trade secrets suit fail.

South Korean biotech ToolGen has won court approval to patent its genome editing technology CRISPR, after an earlier bid to protect its IP found the revolutionary technology was not patentable.

Game maker Light & Wonder is fighting orders requiring it to hand over information to Aristocrat Gaming for a possible suit alleging it and two former employees who jumped ship misused confidential information about Aristocrat’s popular Lightning Link and Dragon Link games.

Casino gaming giant Aristocrat may sue competitor Light & Wonder and two former employees who jumped ship for allegedly misusing confidential information about its popular Lightning Link and Dragon Link games to develop a competing product.

Jones Day is growing its domestic financial markets team with the recruitment of a partner from Baker McKenzie and the transfer of a 17-year veteran from the firm’s London office.

The High Court has agreed to weigh in on a 16-year battle between the federal government and French drug maker Sanofi-Aventis over an allegedly unjustified court order that prevented the release of a generic version of blockbuster blood-thinner Plavix.

Nuix had information in January 2021 which undermined the growth story presented to the market in the prospectus for its IPO, a court has heard on the first day of ASIC’s case against the tech company and a handful of former directors.

Ernst & Young has won a temporary stay of a lawsuit by Billabong founder Gordon Merchant alleging the firm gave negligent advice on how to structure the 2015 sale of bio plastics manufacturer Plantic Technologies.

Sanofi has lost its bid to limit evidence from experts for Amgen in a patent dispute over a cholesterol-lowering antibody, with a judge dismissing concerns about Amgen having a majority of experts giving concurrent evidence. In an application filed at the beginning of the month, the French pharmaceutical company sought to bar Amgen from relying…